Form 4: Sarepta Therapeutics EVP Cristin Rothfuss Reports Stock Transactions

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports the acquisition and disposal of company stock and stock options.

Summary

• On March 10, 2025, Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, engaged in transactions involving the company's stock.
• Rothfuss disposed of 491 shares of common stock at a price of $100.13 to cover tax obligations related to vesting restricted stock units.
• Rothfuss also acquired 8,276 shares of common stock through the granting of restricted stock units (RSUs).
• Additionally, Rothfuss acquired options to purchase 16,644 shares of common stock at an exercise price of $99.69, vesting incrementally from March 10, 2026.
• Following these transactions, Rothfuss directly owns 12,834 shares of common stock and has rights to 16,644 stock options and 21,110 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The granting of RSUs and options is generally positive, but the sale of shares for tax obligations is a standard practice.

Positives

• The granting of RSUs and stock options to a key executive like the EVP and General Counsel can be seen as a positive incentive for continued performance and alignment with shareholder interests.

Negatives

• The sale of shares to cover tax obligations, while common, could be interpreted as a slight negative, although it's a standard practice.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, insider transactions are always subject to scrutiny and potential legal challenges if not conducted properly.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a multi-year commitment from the executive.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions. It's common for executives at publicly traded companies, especially in the biotech sector, to receive stock options and RSUs as part of their compensation packages. These transactions are closely monitored by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to retain talent and align executive interests with shareholder value.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, as the sale of shares might slightly dilute ownership.
• The granting of RSUs and options incentivizes the executive, potentially benefiting shareholders in the long run.

Key Dates